Quick Answer
Immuneering Corp reported Diluted EPS of $1.27 per share (loss) for fiscal year 2025.
Immuneering Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.27 | +37.7% |
| 2024 | -$2.04 | -8.5% |
| 2023 | -$1.88 | +1.6% |
| 2022 | -$1.91 | +22.4% |
| 2021 | -$2.46 | +28.5% |
| 2020 | -$3.44 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.38 | +22.4% | +5.0% |
| June 30, 2025 | -$0.40 | +14.9% | +4.8% |
| March 31, 2025 | -$0.42 | +14.3% | +14.3% |
| September 30, 2024 | -$0.49 | -14.0% | -4.3% |
| June 30, 2024 | -$0.47 | -9.3% | +4.1% |
| March 31, 2024 | -$0.49 | +3.9% | -14.0% |
| September 30, 2023 | -$0.43 | +12.2% | +0.0% |
| June 30, 2023 | -$0.43 | +2.3% | +15.7% |
- Immuneering Corp showed an increase of +37.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Immuneering Corp’s diluted eps has grown by 63.1% (from $3.44 per share (loss) to $1.27 per share (loss)).
- The most recent figure is from Immuneering Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: